Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-06-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic exposure to (cigarette smoke) CS causes biological changes, including airway remodeling and changes in baseline gene expression profiles at the level of the epithelium. Our own data indicate that chronic exposure to CS suppresses the ability of epithelial cells to enhance antiviral gene expression in response to influenza infection and activate host defense responses. While there is a large body of evidence supporting the notion that exposure to CS causes significant changes in host defense responses, which may be linked to permanent changes in epithelial cells at the genomic level, it is not known whether new and emerging tobacco products have similar or distinct effects.

Using live attenuated influenza virus (LAIV) inoculation in human volunteers, this study will compare influenza-induced responses in non-smokers (NS), cigarette smokers (CS), e-cigarette smokers (EC), hookah smokers (HS), and Little Cigar smokers (LCS) in vivo. This will be done by analyzing nasal viral titers, antiviral defense responses, inflammatory mediator production, and markers of immune responses for LAIV-induced responses between the different groups of volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cigarette Smoke and Susceptibility to Influenza Infection

NCT00448617

Healthy

COMPLETED

Menthol, Inflammation, and Nicotine Transition Study

NCT06232447

Cigarette Smoking Inflammatory Response

RECRUITING NA

Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes

NCT01681875

Tobacco Dependence

COMPLETED NA

Identifying Treatments to Motivate Smokers to Quit

NCT01122238

Smoking Smoking Cessation Motivation +1 more

COMPLETED PHASE4

Clinical Response to Biomarker Documentation of Child Secondhand Smoke Exposure

NCT01145729

Biomarker Feedback Smoking Cessation Secondhand Smoke Exposure +1 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cigarette smoke (CS), e-cigarette smoke (EC), hookah smoke (HS), and Little Cigar smoke (LCS)-exposed populations will be stratified based on their responses to a smoking diary, protocol questionnaire, as well as urine cotinine levels (which should be present in all three groups). We are aware that many current smokers are poly-tobacco product users (i.e. smoke cigarettes in addition to non-cigarette products), which could be confounding our observations. This will be controlled for by having potential volunteers complete a smoking diary and provide daily urine samples for 1 week prior to enrolling in the study. Based on this diary, subjects will be grouped as CS (cigarettes only), EC (e-cigarette smokers and smoking less than ½ pack of cigarettes per week), HS (hookah smokers and smoking less than ½ pack of cigarettes per week), and LCS (little cigar smokers and smoking less than ½ pack of cigarettes per week). Individuals with mixed exposures that exceed those described above (i.e. smoking more than ½ pack of cigarettes per week in addition to smoking hookah, e-cigarettes, or Little Cigars) will be excluded from the studies. Potential subjects will then complete a questionnaire regarding their smoking history, and will undergo urine collection for measurement of cotinine for 7 consecutive days. Subjects will be assigned to the different groups as followed: Group NS (no routine exposure to tobacco smoke, and average log10 urine cotinine/creatinine ratio \< 1.0), Group CS (active cigarette smoker and log10 urine cotinine/creatinine ratio \> 4), Group EC (active e-cigarette smokers and average log10 urine cotinine/creatinine ratio 1-4), Group HS (active routine hookah smokers and average log10 urine cotinine/creatinine ratio 1-4), or Group LCS (active routine Little Cigars smoker and average log10 urine cotinine/creatinine ratio 1-4).

Study protocol outline:

Screening visit (2-4 weeks prior to Day 0): Obtain informed consent, history (including smoke exposure questionnaire), physical examination, vital signs (VS), blood draw (for anti-influenza antibody titer, HIV and T cell stimulation with flu antigen), urine (for cotinine), nasal lavage (NL, for differential cell count, viral culture and antigen detection, cytokine panel), nasal epithelial lining fluid (ELF, collected with filter paper for cytokine analysis), nasal epithelial biopsy (NB) #1, pregnancy test for females of child bearing potential. In addition, smokers will undergo spirometry.

Subjects will return to the research lab daily the for the week prior to D0 to provide a urine sample for cotinine. Subjects will given a daily smoking/exposure diary during this time to continue throughout the study.

Day 0 (Monday): Obtain VS, NL, ELF, urine. Administer FluMist.

Day 1 (Tuesday): Obtain VS, NL, ELF, urine, NB #2

Day 2 (Wednesday): Obtain VS, NL, ELF, urine

Day 8 +/- 1 day (Monday-Wednesday): Obtain VS, NL, ELF, urine, NB #3

Day 21 +/- 7 days: Obtain VS, blood draw, collect completed smoking/exposure diary

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza, Human Smoking Respiratory Tract Infections Habits

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LAIV (FluMist)

All subjects will receive a 0.2 mL dose of LAIV (FluMist) once during the study.

LAIV

Intervention Type BIOLOGICAL

Standard dose of LAIV administered by a licensed health care providers.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LAIV

Standard dose of LAIV administered by a licensed health care providers.

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FluMist

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, young nonsmoking adults age 18-45 years who are not routinely exposed to environmental tobacco smoke
* Healthy, young adults age 18-45 years who are active regular smokers (will be stratified based on cigarette, hookah, and Little Cigars)

Exclusion Criteria

* Pregnancy or nursing;
* history of egg allergy;
* history of allergic rhinitis;
* aspirin therapy;
* asthma;
* immunodeficiency (HIV or other);
* on immunosuppressive drugs including corticosteroids;
* history of Guillain-Barre Syndrome;
* smokers with a forced expiratory volume in 1 second (FEV1) less than 75% predicted at screen;
* Chronic obstructive pulmonary disorder (COPD), cardiac disease, or any chronic cardiorespiratory condition;
* febrile and/or respiratory illness within past 3 weeks prior to entry into study

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes